Recent
studies have shown that the epigenetic protein histone deacetylase
11 (HDAC11) is highly expressed in the brain and critically modulates
neuroimmune functions, making it a potential therapeutic target for
neurological disorders. Herein, we report the development of PB94,
which is a novel HDAC11 inhibitor. PB94 exhibited potency and selectivity
against HDAC11 with IC50 = 108 nM and >40-fold selectivity
over other HDAC isoforms. Pharmacokinetic/pharmacodynamic evaluation
indicated that PB94 possesses promising drug-like properties. Additionally,
PB94 was radiolabeled with carbon-11 as [11C]PB94 for positron
emission tomography (PET), which revealed significant brain uptake
and metabolic properties suitable for drug development in live animals.
Furthermore, we demonstrated that neuropathic pain was associated
with brain upregulation of HDAC11 and that pharmacological inhibition
of HDAC11 by PB94 ameliorated neuropathic pain in a mouse model. Collectively,
our findings support further development of PB94 as a selective HDAC11
inhibitor for neurological indications, including pain.